Short-Term Neurodevelopmental Outcome in Term Neonates Treated with Phenobarbital versus Levetiracetam: A Single-Center Experience by Falsaperla, R. et al.
Clinical Study
Short-Term Neurodevelopmental Outcome in Term
Neonates Treated with Phenobarbital versus Levetiracetam:
A Single-Center Experience
Raffaele Falsaperla ,1,2 Laura Mauceri,1 Piero Pavone ,3 Massimo Barbagallo,4
Giovanna Vitaliti ,2 Martino Ruggieri,5 Francesco Pisani,6 and Giovanni Corsello7
1Neonatal Intensive Care Unit, Santo Bambino Hospital, University Hospital “Policlinico-Vittorio Emanuele”, Via Tindaro 2,
95124 Catania, Italy
2Unit of Pediatrics and Pediatric Emergency, University Hospital “Policlinico-Vittorio Emanuele”, Via Plebiscito 628,
95124 Catania, Italy
3Department of Pediatrics, AOU Policlinico-Vittorio Emanuele, University of Catania, Via S. Soﬁa 78, 95123 Catania, Italy
4Department of Pediatrics, Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi, Catania, Italy
5Unit of Rare Diseases of the Nervous System in Childhood, Department of Clinical and Experimental Medicine, Section of Pediatrics
and Child Neuropsychiatry, University of Catania, 95124 Catania, Italy
6Child Neuropsychiatry Unit, Medicine & Surgery Department, Neuroscience Division, University of Parma, Parma, Italy
7Department of Maternal and Child Health, University of Palermo, Palermo, Italy
Correspondence should be addressed to Raﬀaele Falsaperla; raﬀaelefalsaperla@hotmail.com
Received 29 January 2019; Revised 8 April 2019; Accepted 14 April 2019; Published 2 June 2019
Academic Editor: Nicola Tambasco
Copyright © 2019 Raﬀaele Falsaperla et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Background. Phenobarbital (PB) has been traditionally used as the ﬁrst-line treatment for neonatal seizures. More recently,
levetiracetam (LEV) has been increasingly used as a promising newer antiepileptic medication for treatment of seizures in
neonates. Objectives. The aim of our study was to compare the eﬀect of PB vs. LEV on short-term neurodevelopmental outcome
in infants treated for neonatal seizures. Method. This randomized, one-blind prospective study was conducted on term neonates
admitted to the Neonatal Intensive Care Unit of S. Bambino Hospital, University Hospital “Policlinico-Vittorio Emanuele,”
Catania, Italy, from February 2016 to February 2018. Thirty term neonates with seizures were randomized to receive PB or LEV;
the Hammersmith Neonatal Neurological Examination (HNNE) was used at baseline (T0) and again one month after the initial
treatment (T1). Results. We found a signiﬁcantly positive HNNE score for the developmental outcomes, speciﬁcally tone and
posture, in neonates treated with LEV. There was no signiﬁcant improvement in the HNNE score at T1 in the neonates treated
with PB. Conclusion. This study suggests a positive eﬀect of levetiracetam on tone and posture in term newborns treated for
neonatal seizures. If future randomized-controlled studies also show better eﬃcacy of LEV in the treatment of neonatal seizures,
LEV might potentially be considered as the ﬁrst-line anticonvulsant in this age group.
1. Introduction
Seizures are one of the most frequent neurological disorders
during the ﬁrst 28 days of life with an incidence of 2.29 per
1000 live births [1].
The detrimental eﬀect of seizures on the neurodevelop-
mental outcome of newborns is well recognised, further
highlighting the need for a safe antiepileptic medication
without negative eﬀect on the infants’ development [2].
The most common antiepileptic drugs used in Neonatal
Intensive Care Units (NICU) are phenobarbital (PB) and
phenytoin (PHT) [3, 4]. According to the Guidelines on
Neonatal Seizures, published in 2011, the ﬁrst choice of
treatment for neonatal seizures remains PB [5–7], even
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though PB is eﬀective in less than 50% of cases [8–10]. More-
over, PB is associated with several side eﬀects, among them,
its negative eﬀect on psychomotor development and neuro-
logical outcomes [11, 12]. For these reasons, therapeutical
alternatives for neonatal seizures have been explored. Among
the new antiepileptic drugs (AEDs) [13, 14], levetiracetam
(LEV) has been approved as add-on therapy for the treat-
ment of focal seizures in patients over 4 years of age in
Europe. LEV appears to have an excellent tolerability in neo-
nates [15, 16]. Its antiepileptic eﬀect is based on the binding
of the synaptic vesicle protein 2 (SV2) at the presynaptic ter-
minal [17]. LEV appears to have good eﬃcacy; a favourable
safety proﬁle and its rapid intravenous administration are
not associated with cardiovascular adverse eﬀects [18].
One of the uncommon side eﬀects described in therapy
with LEV was increased irritability and tiredness [19, 20]
whereas therapy with PB can induce sedation and respiratory
depression.
In animal models, LEV also seems to be safer than PB. PB
exposure with dosages similar to those used in humans seems
to induce neuronal apoptosis in the developing rat brain [21],
whereas LEV does not induce cell death [22]. PB, but not
LEV, has been found to interfere with maturation of synaptic
connections [23, 24]. Increased schizophrenic-like behav-
ioural outcome was reported in rats treated with PB [25].
No neurotoxic eﬀect of levetiracetam was found in the
developing rat brain [22], and a neuroprotective eﬀect on
hypoxic-ischemic brain injury in neonatal rats or rodent
was conﬁrmed by several studies [17, 22, 26–28].
Clinical studies have reported concerns of signiﬁcant
cognitive and motor impairments related to PB exposure,
especially in pediatric populations [12, 29]. Potential neuro-
toxicity of PB has also been raised.
To date, there are only few reports of using LEV for the
treatment of neonatal seizures, and its eﬀects on develop-
mental outcomes in particular remain unknown. To our
knowledge, only the study by Maitre et al. looked at the
developmental outcomes of the antiepileptic treatment as
the primary objective. This study showed negative eﬀects of
PB but a positive association between the use of LEV and
improved neurodevelopmental outcomes [30].
Here, we report the results of our randomized, one-
blind prospective study conducted on two groups of term
neonates with seizures, who were treated with either LEV
or PB. The neurodevelopmental outcomes were measured
using the Hammersmith Neonatal Neurological Examination
(HNNE), at baseline and again after 1 month of treatment.
2. Materials and Methods
2.1. Study Design. This was a randomized, one-blind pro-
spective study conducted on term newborns receiving PB
or LEV as ﬁrst-line treatment for seizure control. We
included patients admitted to the Neonatal Intensive Care
Unit (NICU), S. Bambino Hospital, University Hospital
“Policlinico-Vittorio Emanuele,” Catania, Italy, between
February 2016 and February 2018. In this period, 4636
deliveries were recorded in our Hospital.
We included term neonates with seizures manifesting
within the ﬁrst 28 days of life. The seizure semiologies
included clonic or tonic-clonic seizures, ocular abnormal
movements, and subtle motor manifestations, such as tongue
thrusting, cycling limb movements, or apnea.
We classiﬁed neonatal seizures into 3 main categories
according to the ILAE criteria on neonatal seizures: (a) “acute
symptomatic seizures (ASS),” caused by acute diseases,
including asphyxia, stroke, meningoencephalitis, and other
acute lesions, such as those secondary to the hypoxic ische-
mic disease; (b) seizures secondary to chronic structural
brain abnormalities (congenital malformations, encephalo-
malacia, and other cerebral lesions), deﬁned as “structural
epilepsy” (SE); and (c) seizures secondary to a genetic condi-
tion (ionic channel diseases, vitamin-dependent epilepsies, or
other epileptogenic diseases without underlying structural
abnormalities), deﬁned as “genetic epilepsy” (GE) [31].
Newborns with SE, GE, and seizures secondary to
transient metabolic disorders, including hypoglycemia and
hypocalcemia; neonates with a positive history for maternal
drug ingestion; those who received more than one anticon-
vulsant medication; and those neonates in whom LEV was
used as second-line therapy were excluded to make the
clinical sample as homogeneous as possible.
The underlying etiologies for seizure onset included
hypoxic-ischemic encephalopathy not requiring therapeu-
tical hypothermia, stroke, and central nervous system
(CNS) infections.
In all the patients, the onset of seizures was in the ﬁrst 72
hours of life. 50% of the patients experienced reduction in the
seizure burden (SB) within the ﬁrst 6 hours from AED initi-
ation, and 100% were seizure-free 1 week after introducing
the treatment. Therapy was maintained for one month after
the seizures resolved.
All neonates underwent a clinical and diagnostic evalua-
tion at baseline (T0), before starting the anticonvulsant
treatment, and then again after 1 month of therapy (T1).
The short-term neurological outcomes were measured using
the Hammersmith Neonatal Neurological Examination.
In order to evaluate the safety of PB vs. LEV, we
recorded the onset of any emerging adverse event, includ-
ing neurological symptoms and kidney and renal function
alterations. None of the patients needed mechanical respi-
ratory assistance.
At baseline, the following data were collected: patients’
demographic data, familial and maternal gestational history,
age of neonates, and clinical description of signs and/or
symptoms, with inclusion and exclusion criteria evaluation.
A complete laboratory assessment including glucose,
electrolytes, urine toxicology screen, thyroid hormones, and
metabolic screening (serum amino acid levels, blood ammo-
nia, and urinary level of fatty acids) was performed. Head
ultrasounds were performed on all neonates before and after
the treatment. All included patients underwent serial video-
EEG recordings.
The participants became eligible for the study after their
parents signed a study consent form, by which they agreed
to the diagnostic and therapeutic intervention, as well as to
the study data collection.
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The study protocol conformed to the ethical guidelines of
the 1975 Declaration of Helsinki as revised in 2000 [32] and
was approved by the ethic committee of the University of
Catania, Italy.
All authors declare not to present any conﬂict of interest
in the publication of the present study.
2.2. Treatment Protocols. Newborns were randomly assigned
to receive PB and LEV in a blinded manner. The drugs were
administered at the following doses: intravenous (IV) PB
with an initial dose of 20 mg/kg, followed by a maintenance
dose of oral PB at 5 mg/kg; IV LEV at an initial dose of 20
mg/kg, followed by a maintenance dose of oral LEV at 20
mg/kg, with gradually increasing doses up to 40 mg/kg twice
daily in case of nonresponse at initial doses. PB was adminis-
tered according to the Italian Society of Neonatology guide-
lines [33]. LEV was administered according to the
recommendations published by Yau et al. in 2015 [34].
2.3. Outcome Measures. We performed the Hammersmith
Neonatal Neurological Examination (HNNE) at baseline
(T0) and after one month of treatment (T1). The Ham-
mersmith Neonatal Neurological Examination (HNNE)
developed by Dubowitz and Dubowitz is widely used in
newborns for their neurological assessment [35]. The
Hammersmith score was evaluated by trained neonatolo-
gists of our NICU, who evaluated the following neurolog-
ical items: (1) tone and posture, (2) tone patterns, (3)
movements, (4) reﬂexes, (5) abnormal signs, and (6) ori-
entation and behaviour.
2.4. Statistical Analysis. For statistical evaluation, we used
dedicated software: JMP (product of SAS Institute Inc.,
Cary, NC 27513-2414, USA) and GraphPad 5.0 (La Jolla,
CA, USA). We reported qualitative variables as percentage
and quantitative ones as mean ± standard deviation. For
those variables presented as mean ± standard deviation,
normal distribution was checked by the Kolmogorov-
Smirnov one-sample test and statistics for kurtosis and
symmetry. The chi-square test was used to compare qual-
itative variables. The Student t-test was used to compare
quantitative results.
P values under 0.05 were considered statistically
signiﬁcant.
3. Results
We included 30 neonates, 12 females and 18 males, with a
mean gestational age of 38 30 ± 1 30weeks. The demo-
graphic data of the two groups are shown in Table 1. All
patients were aﬀected by acute symptomatic seizures
(ASS) and particularly stroke, CNS infection, and
hypoxic-ischemic encephalopathy not requiring therapeu-
tic hypothermia.
The neurological assessment, the seizures types, and the
Hammersmith score performed at baseline in the two groups
are shown in Table 2. The Hammersmith score and each
single item showed better scores at T1, with signiﬁcant diﬀer-
ences between T0 and T1 (P = 0 001) in the LEV group.
Among the single items, tone and posture, reﬂexes, orienta-
tion, and behaviour showed a statistical improvement. No
signiﬁcant diﬀerences between T0 and T1 were reported in
the PB group (Table 3).
In Figure 1, we summarize in a ﬂow chart the clinical fea-
tures of our patients and the achieved results.
4. Discussion
Our study found that neonates with seizures who were
treated with LEV showed better HNNE test scores 1
month after treatment initiation, compared to neonates
treated with PB.
The HNNE is a test developed for the clinical assessment
of term and preterm infants at risk of developmental delay. It
is a speciﬁc and predictive test that evaluates posture and
tone, reﬂexes, movements, and neurobehavioral responses.
Literature data showed that the HNNE test is able to predict
cerebral palsy with a sensitivity range of 57-86% and speciﬁc
range of 45-83% when carried out before term age [35].
In 2018, a ﬁrst systematic review on the eﬃcacy of LEV in
the treatment neonatal seizures was published by McHugh
et al. [36]. Their study was the ﬁrst to examine the eﬃcacy
of LEV compared to PB in neonates. The authors demon-
strate the clinical equipoise between LEV and PB in the
setting of neonatal seizures. They conclude that LEV does
not appear to be neurotoxic and it may potentially oﬀer
fewer and/or less severe long-term cognitive eﬀects, when
compared to phenobarbital with its known, potentially
neurotoxic eﬀects.
Table 1: Demographic data.
LEV group PB group
P value, Student t-test, and
chi-square test
Number of patients 15 15
Gestational age 38 13 ± 1 24 38 33 ± 1 04 NS
Sex (F/M) 4/11 8/7
Prenatal anomalies 40% 40% NS
APGAR score 1 min. 7 66 ± 1 29 8 66 ± 0 89 NS
APGAR score 5 min. 9 13 ± 1 12 9 03 ± 0 84 NS
Respiratory distress 33.33% 40% NS
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Two large multicentric studies of intravenous LEV use
are currently under way. The ﬁrst, LEVNEONAT, is a multi-
center French clinical trial with the aim to develop new treat-
ment strategies for the treatment of neonatal seizures using
levetiracetam. The purpose of this study is to determine the
correct dosing, safety, and eﬃcacy of the intravenous leveti-
racetam as a ﬁrst-line treatment in term newborns with sei-
zures secondary to HIE. Their ﬁrst clinical data seem to
conﬁrm that LEV is a promising treatment for seizures in
newborns [37, 38]. The aim of the second study is to deter-
mine the eﬃcacy of intravenous LEV, as a ﬁrst-line anticon-
vulsant for treatment of neonatal seizures, compared to
phenobarbital. Seizure burden will be based on duration
and frequency of seizure events [39].
To date, there are only few clinical studies focused on
neonatal seizures treated with LEV.
Hmaimess et al. [40] reported on a neonate with seizures
unresponsive to traditional therapy. Abend et al. [16]
Table 3: Changes in the Hammersmith score in the PB group and in the LEV group.
PB group before treatment PB group after treatment P value
Hammersmith score (tot.) 27 83 ± 3 25 28 63 ± 2 73 0.26
Tone and posture score 7 6 ± 0 96 8 03 ± 0 93 0.45
Tone pattern score 4 33 ± 0 72 4 30 ± 0 61 0.27
Movements 2 73 ± 0 45 2 86 ± 0 35 0.17
Reﬂexes 4 76 ± 0 59 4 9 ± 0 47 0.20
Abnormal signs 2 93 ± 0 25 2 98 ± 0 30 0.74
Orientation and behaviour 5 45 ± 1 03 5 33 ± 0 97 0.41
LEV group before treatment LEV group after treatment P value
Hammersmith score (tot.) 27 33 ± 4 03 32 4 ± 1 75 0.001
Tone and posture score 7 5 ± 1 18 9 36 ± 0 76 0.05
Tone pattern score 4 3 ± 0 64 4 75 ± 0 46 0.11
Movements 2 56 ± 0 49 3 1 ± 0 5 0.52
Reﬂexes 4 86 ± 0 89 5 56 ± 0 49 0.01
Abnormal signs 2 8 ± 0 41 3 1 ± 0 5 0.76
Orientation and behaviour 5 16 ± 1 01 6 7 ± 0 45 0.02
Table 2: Neurological assessment, seizures types, EEG study, and Hammersmith score of the LEV and PB groups before treatment.
Orientation and behaviour
5 45 ± 1 03 5 33 ± 0 97 0.41
LEV group PB group P value
Neurologic examination Abnormal: 46% Abnormal: 40% 0.31
Seizures types
Automatism: 13.33% Automatism: 6.66%
Tonic seizures: 26.66% Tonic seizures: 20%
Multifocal clonic seizures: 20% Multifocal clonic seizures: 26.66%
Focal clonic seizures: 40%
Focal clonic seizures: 40%
Autonomic seizures: 6.66%
EEG background study
Discontinuity 85% 90%
Burst suppression 15% 10%
Hammersmith score
Hammersmith score (tot.) 27 33 ± 4 03 27 83 ± 3 25 0.21
Tone and posture score 7 5 ± 1 18 7 6 ± 0 96 0.40
Tone pattern score 4 3 ± 0 64 4 33 ± 0 72 0.57
Movements 2 56 ± 0 49 2 73 ± 0 45 0.58
Reﬂexes 4 86 ± 0 89 4 76 ± 0 59 0.06
Abnormal signs 2 8 ± 0 41 2 93 ± 0 25 0.90
Orientation and behaviour 5 16 ± 1 01 5 45 ± 1 03 0.42
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described 24 neonates with seizures where the treatment with
LEV at maintenance doses of 10-80 mg/kg/day resulted in
clinical improvement. Khan et al. [19] treated neonates
with seizures using IV LEV at the dose of 25 mg/kg/day.
Ramantani et al. [20] extended their study to 38 newborns
with seizures. Rakshasbhuvankar et al. [18] treated eight
neonates with IV LEV.
Falsaperla et al. [41] reported on 16 neonates, 12 born
at term and 4 preterm. Neonates responded to treatment
with a variable range of seizure resolution ranging from
24 h to 15 days. Twelve neonates with seizures were
studied by Yau et al. [34]. LEV has also been adminis-
tered as adjunctive therapy by Shoemaker and Rotenberg
[42] in three neonates with seizures treated with PB and
PHT, PHT, and PHT plus CMZ. In all patients, LEV
proved to be eﬀective without adverse eﬀects. In
Table 4, we summarize the results of these reports in
more detail.
Included neonates (N = 30)
Excluded neonates (N = 6)
LEV group
N = 15
F/M = 4/11
PB group
N = 15
F/M = 8/7
Hammersmith
score tot. (T0)
27.33 ± 4.03 
Hammersmith
score tot. (T0)
27.83 ± 3.25 
Hammersmith
score tot. (T1)
32.4 ± 1.75 
Hammersmith
score tot. (T1)
28.63 ± 2.73 
Eligible and consented neonates
N = 36
Seizures onset in the first 72 h of life
LEV group
3 of 15 required increasing
dose up to 40 mg/kg
PB group
Not modified dosage
50% with seizure-burden reduction in the first 6 h from
AED beginning
100% seizure-free within 1 week from AED beginning 
(i)
(ii)
(iii)
(iv) Onset later than72 h of life (2)
Therapeutic
 hypothermia (1)
Pyridoxine-
dependent (1)
Hypoglycemia (2)
(i)
(ii)
(iii) CNS infection (4)
Stroke (3)
HIE (23)
Figure 1: Flow diagram of recruitment, outcomes, and antiepileptic drugs (AED) used in two cohorts.
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To our knowledge, only the study by Maitre et al., a
single large retrospective study of 280 infants, whose sei-
zures were treated with either LEV or PB, compared the
eﬀects of these drugs on the neurodevelopment outcome
[30]. The authors included all patients with at least one
witnessed clinical seizure who received PB or LEV. They
assessed neurodevelopmental outcomes by measuring
motor, cognitive, and language performance on the Devel-
opmental Assessment of Young Children (DAYC) at 12
months of age and by using the Bayley Scales of Infant
Development (BSID) at 24 months. Their study suggested
that exposure to PB might be associated with worse neuro-
developmental outcomes at 2 years of age and that LEV
may be associated with improved outcomes compared to
PB. Regarding cognitive and motor scores the eﬀect were
less evident with LEV.
However, none of the reported studies explored the
short-term inﬂuence of the antiepileptic drugs measured by
the neurological examination of the newborns one month
after the initiation of the treatment. In our study, we demon-
strated an improvement of the short-term neurological
outcomes in neonates treated with LEV compared to those
treated with PB. Our results suggest that LEV, with its pre-
sumed neuroprotective action and safer side-eﬀect proﬁle,
might represent a good alternative for the treatment of neo-
natal seizure especially in those patients with an abnormal
neurological examination.
Nevertheless, further clinical studies are needed to prove
the eﬃcacy of LEV in neonatal age, given its beneﬁts on the
neurological development of these patients.
4.1. Limitation. Our study has a few limitations. First is the
small number of patients. We also included patients with a
variety of etiologies within the group of acute symptomatic
seizures (ASS). Lastly, a limitation of the study is also the lack
of a long-term outcome.
However, we believe that despite the limitations, our
study might serve as a ﬁrst step in the development of larger
double-blind placebo-controlled trials in order to assess for
potentially protective eﬀect of LEV.
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